A Goldhirsch
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Mauriac L, Castiglione-Gertsch M, Price K, Coates A, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group, Gelber R, Nogaret J, Keshaviah A, Debled M, Mouridsen H, Forbes J, Thürlimann B, Paridaens R, Monnier A, Láng I, Wardley A, International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007; 18:859-67.
01.05.2007Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
01.05.2007Ann Oncol 2007; 18:859-67
Mauriac L, Castiglione-Gertsch M, Price K N, Coates A S, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group, Gelber R D, Nogaret J-M, Keshaviah A, Debled M, Mouridsen H, Forbes J F, Thürlimann Beat, Paridaens R, Monnier A, Láng I, Wardley A, International Breast Cancer Study Group
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
Keshaviah A, Coates A, Gelber R, Castiglione Gertsch M, Simoncini E, Pagani O, Price K, Aebi S, Mendiola C, Thürlimann B, Colleoni M, Collins J, Crivellari D, Lindtner J, Rotmensz N, Dellapasqua S, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 2007; 18:701-8.
01.04.2007CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
01.04.2007Ann Oncol 2007; 18:701-8
Keshaviah A, Coates A S, Gelber R D, Castiglione Gertsch M, Simoncini E, Pagani O, Price K N, Aebi S, Mendiola C, Thürlimann Beat, Colleoni M, Collins J, Crivellari D, Lindtner J, Rotmensz N, Dellapasqua S, Goldhirsch A
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
Perey L, Goldhirsch A, Köberle D, Clément P, Dietrich D, Fiche M, Wildiers H, Nolé F, Zaman K, Hawle H, Paridaens R, Thürlimann B. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007; 18:64-9.
01.01.2007Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
01.01.2007Ann Oncol 2007; 18:64-9
Perey L, Goldhirsch A, Köberle Dieter, Clément P, Dietrich D, Fiche M, Wildiers H, Nolé F, Zaman K, Hawle H, Paridaens R, Thürlimann Beat
First--select the target: better choice of adjuvant treatments for breast cancer patients
Goldhirsch A, Coates A, Gelber R, Glick J, Thürlimann B, Senn H, St Gallen Expert Panel Members. First--select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 2006; 17:1772-6.
01.12.2006First--select the target: better choice of adjuvant treatments for breast cancer patients
01.12.2006Ann Oncol 2006; 17:1772-6
Goldhirsch A, Coates A S, Gelber R D, Glick J H, Thürlimann Beat, Senn H-J, St Gallen Expert Panel Members
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005
Goldhirsch A, Glick J, Gelber R, Coates A, Thürlimann B, Senn H, Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16:1569-83.
01.10.2005Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005
01.10.2005Ann Oncol 2005; 16:1569-83
Goldhirsch A, Glick J H, Gelber R D, Coates A S, Thürlimann Beat, Senn H-J, Panel members
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
Pagani O, Longhi S, Ruggeri M, Graffeo R, Hess D, Thürlimann B, Lombardi D, Crivellari D, Munzone E, Nolé F, Sessa C, Goldhirsch A. Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer. Ann Oncol 2005; 16:1609-17.
01.10.2005Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
01.10.2005Ann Oncol 2005; 16:1609-17
Pagani O, Longhi S, Ruggeri M, Graffeo R, Hess D, Thürlimann Beat, Lombardi D, Crivellari D, Munzone E, Nolé F, Sessa C, Goldhirsch A
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
Colleoni M, Veronesi A, Holmberg S, Erzen D, Forbes J, Murray E, Thürlimann B, Simoncini E, Pagani O, Collins J, Crivellari D, Rudenstam C, Lindtner J, Price K, Castiglione-Gertsch M, Coates A, Gelber R, Li S, Goldhirsch A. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol 2005; 16:716-25.
01.05.2005Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
01.05.2005Ann Oncol 2005; 16:716-25
Colleoni M, Veronesi A, Holmberg S, Erzen D, Forbes J, Murray E, Thürlimann Beat, Simoncini E, Pagani O, Collins J, Crivellari D, Rudenstam C-M, Lindtner J, Price K N, Castiglione-Gertsch M, Coates A S, Gelber R D, Li S, Goldhirsch A
Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
Hess D, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann B, Swiss Group of Clinical Cancer Research (SAKK). Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5.
01.12.2004Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
01.12.2004Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5
Hess Dagmar, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann Beat, Swiss Group of Clinical Cancer Research (SAKK)
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
Bernhard J, Goldhirsch A, Price K, Fey M, Thürlimann B, Veronesi A, Crivellari D, Rudenstam C, Snyder R, Collins J, Perey L, Forbes J, Murray E, Castiglione-Gertsch M, Gelber R, Coates A, Zahrieh D, Hürny C. Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. BJC 2004; 91:1893-901.
29.11.2004Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
29.11.2004BJC 2004; 91:1893-901
Bernhard J, Goldhirsch A, Price K N, Fey M F, Thürlimann Beat, Veronesi A, Crivellari D, Rudenstam C-M, Snyder R, Collins J, Perey L, Forbes J F, Murray E, Castiglione-Gertsch M, Gelber R D, Coates A S, Zahrieh D, Hürny C
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience
Berclaz G, Thürlimann B, Fey M, Mendiola C, Werner I, Simoncini E, Crivellari D, Gelber R, Goldhirsch A, Snyder R, Collins J, Li S, Price K, Coates A, Castiglione-Gertsch M, Rudenstam C, Holmberg S, Lindtner J, Erien D, International Breast Cancer Study Group. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 2004; 15:875-84.
01.06.2004Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience
01.06.2004Ann Oncol 2004; 15:875-84
Berclaz G, Thürlimann Beat, Fey M F, Mendiola C, Werner I Dudley, Simoncini E, Crivellari D, Gelber R D, Goldhirsch A, Snyder R, Collins J, Li S, Price K N, Coates A S, Castiglione-Gertsch M, Rudenstam C-M, Holmberg S B, Lindtner J, Erien D, International Breast Cancer Study Group
Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO)
Fogliata A, Schefer H, Curti G, Schott A, Zenklusen H, Roth A, Morel P, Gertsch P, Gervaz P, Davis J, Székely G, Burger C, Huser M, Kolotas C, Thalmann G, Guillou L, Jichlinski P, von Briel C, Beer K, Miralbell R, Escudé L, Mollà M, Nouet P, Rouzaud M, Mini R, Kemmerling L, Vetterli D, Lütolf U, Ulmer U, Oehler C, Weber D, Bolsi A, Lomax A, Timmermann B, Goitein G, Verwey J, Pedroni E, Rutz H, Lomax A, Weber D, Luthi F, Pasche P, Bentzen S, Khalil A, Dubois J, Pica A, Stupp R, Stadelmann O, Allaoua M, Kebdani T, Slosman D, Dische S, Cummings B, Van den Bogaert W, Horiot J, Saunders M, Isaak B, Pesce G, Popowski Y, Tebeu P, Matzinger O, Betz M, Corminboeuf F, Bouville S, Özsoy O, Bigler R, Vees H, Girardet C, Abdou M, Huguenin P, Verkooijen H, Bouchardy C, Franzetti A, Richetti A, Presilla S, Motta M, Valley J, Bressan S, Bulling S, Pache G, Merçay A, Major A, Usel M, Ludicke F, Rufibach K, Ries G, Coucke P, Wang H, Pasche G, Do H, Balmer A, Munier F, Jargy C, Dipasquale G, Born E, Szczerba D, Hueber P, Hafner H, Cozzi L, Moeckli R, Boehringer T, Collen T, Laluhovà D, Allemann K, Bründler M, Krayenbühl J, Schoenmaker E, Norton I, Baumert B, Rutz H, Pedroni E, Lin S, Coray A, Nicolini G, Vees H, Martineau P, Gourgou S, Zouhair A, Ozsahin M, Cunat S, Larbouret C, Azria A, Bonny C, Hofstetter B, Tenzer A, Krek W, Lutters G, Evans D, Romieu G, Bodis S, Stahel R, Weder W, Jerman M, Schneiter D, Jörger M, Lardinois D, Taverna C, Kestenholz P, Heuberger J, Pèlegrin A, Pujol P, Zimmer Y, Greiner R, Gruber G, Ametamey S, Bodis S, Zingg D, Jochum W, Vuong V, Honer M, Riesterer O, Mhawech P, Verdan C, Tschanz E, Dulguerov P, Ares C, Pruschy M, Inteeworn N, Stalder D, Streit B, Ganapathipillai S, Aebersold D, Berthou S, Kaser-Hotz B, Gassmann M, Rohrer Bley C, Wergin M, Roos M, Höpfl G, Ohlerth S, Allal A, Behrensmeier F, Thürlimann B, Carbone A, Crivellari D, Collins J, Gol-Ouh R, Lindtner J, Holmberg S, Rudenstam C, Castiglione-Gertsch M, Price K, Nasi M, Bonetti M, Simoncini E, Fey M, Bortoluzzi L, Weitzel M, Kranzbuehler H, Becker M, Taussky D, Azria D, Mirimanoff R, Kramar A, Jeanneret Sozzi W, Goldhirsch A, Coates A, Gelber R, Ueltschi G, Lippold B, Kranzbühler H, Bernier J, Studer G, Landmann C, Mahler F, Greiner R, Taverna C, Stanek N, Ciernik I, Friedrich E, Beer K, Balmer Majno S, Hügli A, Gallino A, Juelke P, Pajic B, Curschmann J, Bieri S, Luthi J, Suleiman M, Bargetzi M, Notter M, Thum P, Resink T, Erne P, Jamshidi P, Hafner H, Mach N. Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO). Strahlenther Onkol 2004; 180 Suppl 1:89-108.
01.06.2004Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO)
01.06.2004Strahlenther Onkol 2004; 180 Suppl 1:89-108
Fogliata A, Schefer H, Curti G, Schott A, Zenklusen H, Roth A D, Morel Ph, Gertsch P, Gervaz P, Davis J B, Székely G, Burger C, Huser M, Kolotas C, Thalmann G, Guillou L, Jichlinski P, von Briel C, Beer K, Miralbell R, Escudé L, Mollà M, Nouet P, Rouzaud M, Mini R, Kemmerling L, Vetterli D, Lütolf U M, Ulmer U, Oehler C, Weber D, Bolsi A, Lomax A, Timmermann B, Goitein G, Verwey J, Pedroni E S, Rutz H P, Lomax A J, Weber D C, Luthi F, Pasche P, Bentzen S M, Khalil A A, Dubois J B, Pica A, Stupp R, Stadelmann O, Allaoua M, Kebdani T, Slosman D O, Dische S, Cummings B J, Van den Bogaert W, Horiot J C, Saunders M I, Isaak B, Pesce G, Popowski Y, Tebeu P, Matzinger O, Betz M, Corminboeuf F, Bouville S, Özsoy O, Bigler R, Vees H J, Girardet C, Abdou M, Huguenin P, Verkooijen H, Bouchardy C, Franzetti A, Richetti A, Presilla S, Motta M, Valley J F, Bressan S, Bulling S, Pache G, Merçay A, Major A, Usel M, Ludicke F, Rufibach K, Ries G, Coucke P, Wang H, Pasche G, Do H P, Balmer A, Munier F, Jargy C, Dipasquale G, Born E J, Szczerba D, Hueber P, Hafner H P, Cozzi L, Moeckli R, Boehringer T, Collen T, Laluhovà D, Allemann K, Bründler M-A, Krayenbühl J, Schoenmaker E, Norton I A, Baumert B G, Rutz H, Pedroni E, Lin S, Coray A, Nicolini G, Vees H, Martineau P, Gourgou S, Zouhair A, Ozsahin M, Cunat S, Larbouret C, Azria A, Bonny C, Hofstetter B, Tenzer A, Krek W, Lutters G, Evans D B, Romieu G, Bodis St, Stahel R, Weder W, Jerman M, Schneiter D, Jörger Markus, Lardinois D, Taverna Ch, Kestenholz P, Heuberger J, Pèlegrin A, Pujol P, Zimmer Y, Greiner R H, Gruber G, Ametamey S, Bodis S, Zingg D, Jochum Wolfram, Vuong V, Honer M, Riesterer O, Mhawech P, Verdan C, Tschanz E, Dulguerov P, Ares C, Pruschy M, Inteeworn N, Stalder D, Streit B, Ganapathipillai S, Aebersold D M, Berthou S, Kaser-Hotz B, Gassmann M, Rohrer Bley C, Wergin M, Roos M, Höpfl G, Ohlerth S, Allal A S, Behrensmeier F, Thürlimann Beat, Carbone A, Crivellari D, Collins J, Gol-Ouh R, Lindtner J, Holmberg S B, Rudenstam C-M, Castiglione-Gertsch M, Price K N, Nasi M L, Bonetti M, Simoncini E, Fey M F, Bortoluzzi L, Weitzel M, Kranzbuehler H, Becker M, Taussky D, Azria D, Mirimanoff R O, Kramar A, Jeanneret Sozzi W, Goldhirsch A, Coates A S, Gelber R D, Ueltschi G, Lippold B, Kranzbühler H, Bernier J, Studer G, Landmann Ch, Mahler F, Greiner R, Taverna C, Stanek N, Ciernik I F, Friedrich E E, Beer K T, Balmer Majno S, Hügli A, Gallino A, Juelke Peter D, Pajic B, Curschmann J, Bieri S, Luthi J C, Suleiman M, Bargetzi M, Notter M, Thum Peter, Resink Therese Josephine, Erne Paul, Jamshidi Peiman, Hafner Hans-Peter, Mach N
Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer
Senn H, Thürlimann B, Goldhirsch A, Wood W, Gelber R, Coates A. Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. Breast (Edinburgh, Scotland) 2003; 12:569-82.
01.12.2003Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer
01.12.2003Breast (Edinburgh, Scotland) 2003; 12:569-82
Senn H-J, Thürlimann Beat, Goldhirsch A, Wood W C, Gelber R D, Coates A S
Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann B, Goldhirsch A, Brunner K, Borner M, Swiss Group for Clinical Cancer Research (SAKK). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:1215-21.
01.08.2003Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
01.08.2003Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:1215-21
Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann Beat, Goldhirsch A, Brunner K W, Borner M M, Swiss Group for Clinical Cancer Research (SAKK)
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII
Wallgren A, Collins J, Coates A, Price K, Forbes J, Werner I, Fey M, Thürlimann B, Lindtner J, Holmberg S, Castiglione-Gertsch M, Goldhirsch A, Gelber R, Bonetti M, International Breast Cancer Study Group Trials I through VII. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1205-13.
01.04.2003Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII
01.04.2003Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1205-13
Wallgren A, Collins J, Coates A S, Price K, Forbes J F, Werner I D, Fey M, Thürlimann Beat, Lindtner J, Holmberg S B, Castiglione-Gertsch M, Goldhirsch A, Gelber R D, Bonetti M, International Breast Cancer Study Group Trials I through VII
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
Colleoni M, Collins J, Thürlimann B, Holmberg S, Crivellari D, Beyerle C, Neumann R, Goldhirsch A, International Breast Cancer Study Group, Lindtner J, Schmoor C, Rudenstam C, Litman H, Castiglione-Gertsch M, Sauerbrei W, Gelber R, Bonetti M, Coates A, Schumacher M, Bastert G, German Breast Cancer Study Group. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. British journal of cancer 2002; 86:1705-14.
05.06.2002Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
05.06.2002British journal of cancer 2002; 86:1705-14
Colleoni M, Collins J, Thürlimann Beat, Holmberg S B, Crivellari D, Beyerle C, Neumann R L A, Goldhirsch A, International Breast Cancer Study Group, Lindtner J, Schmoor C, Rudenstam C-M, Litman H J, Castiglione-Gertsch M, Sauerbrei W, Gelber R D, Bonetti M, Coates A S, Schumacher M, Bastert G, German Breast Cancer Study Group
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
Colleoni M, Goldhirsch A, Fey M, Murray E, Simoncini E, Cortes-Funes H, Holmberg S, Thürlimann B, Collins J, Lindtner J, Rudenstam C, Price K, Gelber R, Castiglione-Gertsch M, Coates A, Gelber S, International Breast Cancer Study Group. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001; 19:4141-9.
01.11.2001Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
01.11.2001Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001; 19:4141-9
Colleoni M, Goldhirsch A, Fey M, Murray E, Simoncini E, Cortes-Funes H, Holmberg S B, Thürlimann Beat, Collins J, Lindtner J, Rudenstam C M, Price K, Gelber R D, Castiglione-Gertsch M, Coates A S, Gelber S, International Breast Cancer Study Group
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
Crivellari D, Goldhirsch A, Sessa C, Graffeo R, Martinelli G, Bauer J, Borner M, Hess D, Thürlimann B, Nolé F, Lombardi D, Veronesi A, Pagani O, International Breast Cancer Study Group. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001; 12:353-6.
01.03.2001High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
01.03.2001Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001; 12:353-6
Crivellari D, Goldhirsch A, Sessa C, Graffeo R, Martinelli G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Nolé F, Lombardi D, Veronesi A, Pagani O, International Breast Cancer Study Group
Identifying breast cancer patients at high risk for bone metastases
Colleoni M, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R, Bonetti M, Thürlimann B, Price K, Castiglione-Gertsch M, Coates A, Rudenstam C. Identifying breast cancer patients at high risk for bone metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3925-35.
01.12.2000Identifying breast cancer patients at high risk for bone metastases
01.12.2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3925-35
Colleoni M, Senn H J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R D, Bonetti M, Thürlimann Beat, Price K N, Castiglione-Gertsch M, Coates A S, Rudenstam C M
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study
Pagani O, D'Incalci M, Zucchetti M, Graffeo R, Martinelli G, Bauer J, Borner M, Hess D, Thürlimann B, Lombardi D, Crivellari D, Nolé F, Sessa C, Goldhirsch A. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:985-91.
01.08.2000Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study
01.08.2000Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:985-91
Pagani O, D'Incalci M, Zucchetti M, Graffeo R, Martinelli G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Lombardi D, Crivellari D, Nolé F, Sessa C, Goldhirsch A
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
Aebi S, Coates A, Werner I, Simoncini E, Cortes-Funes H, Crivellari D, Lindtner J, Rudenstam C, Thürlimann B, Collins J, Gelber R, Castiglione-Gertsch M, Gelber S, Goldhirsch A. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet 2000; 355:1869-74.
27.05.2000Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
27.05.2000Lancet 2000; 355:1869-74
Aebi S, Coates A S, Werner I D, Simoncini E, Cortes-Funes H, Crivellari D, Lindtner J, Rudenstam C M, Thürlimann Beat, Collins J, Gelber R D, Castiglione-Gertsch M, Gelber S, Goldhirsch A